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and Barbara W Chwirot1*Abstract
Background: Prognostic value of enhanced COX-2 expression in breast cancer has been controversial for a long
time. The opinions vary widely between studies. Moreover, significant majority of studies considered only COX-2
expression in cancer epithelial cells.
Methods: We examined the prognostic value of COX-2 expression in both epithelial and stromal cells using three
different antibodies and three algorithms of immunohistochemical scoring and categorizing the tumours into COX-2
overexpressing groups.
Results: Our results demonstrate that COX-2 expression in stromal cells is independent prognostic factor indicating worse
overall survival of patients. Such a result was obtained using each of the three antibodies and two of the algorithms used
for evaluations of COX-2 expression levels. We also show that immunohistochemical assessment of the prognostic value
of COX-2 expression in cancer epithelial cells depends to a large extent on a combination of primary antibodies and
algorithms used for determination of the COX-2 over-expressing tumours.
Conclusions: Our results indicate that stromal expression of COX-2 is independent prognostic parameter relatively
insensitive to variations in sensitivity of antibodies used for its determination. Wide scatter of the published results
concerning prognostic value of COX-2 expression in breast cancer tissues seems to be due to a large extent to multitude
of antibodies and scoring algorithms used by different groups.
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Increased expression of cyclooxygenase-2 (COX-2) has
been reported for many types of human cancer including
breast cancer. Moreover, several epidemiologic studies in-
dicate that regular use of non-steroidal anti-inflammatory
drugs (NSAIDs) which inhibit COX-2 reduces incidence
of at least some types of human cancers like sporadic and
familial colon cancer, pancreatic cancer, melanoma and
breast cancer (see for instance [1,2]). Large cohort study
involving ca. 80 000 postmenopausal women showed
21%-28% reduction in the risk of breast cancer for women
taking NSAIDs at least twice a week for 5–10 years [1].* Correspondence: chwirot@biol.uni.torun.pl
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unless otherwise stated.A role of enhanced COX-2 expression in breast cancer
development and progression has not been fully eluci-
dated yet and the literature data on prognostic useful-
ness of COX-2 for the breast cancer are inconsistent.
Several studies associated enhanced COX-2 expression
with a worse survival of patients [3-16]. Other groups,
however, reported that immunohistochemically detected
COX-2 expression did not provide prognostic informa-
tion [17-21].
COX-2 expression in mammary epithelial cells can be
induced in several ways, among others by estrogen re-
ceptors (ER) [22]. On the other hand, COX-2 catalyzes
production of prostaglandins which stimulate aromatase
converting androgens to estrogens [23]. Park et al. [21]
investigated prognostic value of COX-2 for cancers with
and without ER expression and did not find evidence oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lead to a conclusion that increased COX-2 expression is as-
sociated with a worse survival of patients with ER-negative
breast cancers [7,15]. According to immunohistochemical
study of Chuah et al. [11] of tumours of patients subject to
neoadjuvant chemotherapy a low COX-2 expression was
associated with a better survival but only within patients
with ER positive tumours.
Although some studies indicated prognostic value of
COX-2 expression for the breast cancer using univariate
statistical analyses such conclusions were not confirmed
by multivariate analyses including several significant vari-
ables [3,12-14]. Only Denkert et al. [4] found a correlation
between COX-2 expression and survival in multivariate
analysis. It should also be noticed that majority of the au-
thors focused on the COX-2 expression in epithelial cells
of the lesions and did not examine a role of stromal com-
ponents. Other studies demonstrated, however, that out-
comes of breast cancer patients might be assessed through
examination of stromal biomarkers [24] and the study of
Richardsen et al. [16] showed that indeed COX-2 expres-
sion in stroma but not in the epithelial cells was correlated
with a survival of breast cancer patients.
Finally, a validity of immunohistochemical analyses de-
pends to a large extent upon antibody specificity (see for
instance [25-27]). Other factors important for a compar-
ability of the data reported by different groups are sensi-
tivity of antigen detection and differences in algorithms
used for immunohistochemical scoring. In this work we
used three different primary antibodies and three differ-
ent immunohistochemical scoring systems to assess the
expression of the COX-2 protein both in the cancer epi-




The material for study was formalin fixed, paraffin embed-
ded tissue samples obtained from 41 breast cancer patients
who underwent surgery without neoadjuvant chemother-
apy. The study consisted of 41 primary breast tumours
of different expression of steroid hormones receptors
(estrogen - ER, progesterone - PR), HER-2, size (pT1 –
16, pT2 – 14, pT3 – 1, pT4 – 6), and presence of me-
tastases (N0 – 27, N1 – 9, N2 – 3). Tissue specimens
were obtained from the archives of The Tumour Pathology
Department, Maria Skłodowska-Curie Memorial Institute
in Gliwice, Poland. The research has been approved by the
Bioethics Committee at Oncology Center (Ref. No KB/
430-27/14), Gliwice Division, Gliwice, Poland.
Antibodies
COX-2 expression was detected using paralelly three
types of primary antibodies: (i) Ab1 - rabbit monoclonalantibody binding to peptide mapped at the C-end of the
COX-2 protein (SP21 clone: RM-1921, Thermo Fisher
Scientific, Waltham, Massachusetts, USA). The same type
of the antibody was used by the groups reporting con-
tradictory results [12,15]; (ii) Ab2 - mouse monoclonal
antibody detecting peptide mapped at the C-end of the
COX-2 protein (580–599 aa) (CX229 clone, 160112,
Cayman Chemical, Ann Arbor, Michigan, USA). This type
of the antibody has been most commonly used in the
studies of COX-2 expression in breast lesions (at least 30
different studies, among them [3]); (iii) Ab3 - goat poly-
clonal antibody generated against peptide mapped at the
N-end of the COX-2 protein (N-20, sc-1746, Santa Cruz
Biotechnology, Santa Cruz, California, USA) used in the
earlier studies of our group. Primary goat polyclonal anti-
Cox-2 antibody from Santa Cruz Biotechnology was also
applied in the study carried out by Richardsen et al. [16].Immunohistochemistry
The 3 μm sections were dewaxed and rehydrated in
usual manner. The reagents and conditions of the im-
munohistochemical procedures are given in Table 1. We
would like to notice that the typically brown product of
DAB reaction acquires a blue to black color in the pres-
ence of nickel ions. Negative control reactions were car-
ried out with PBS pH 7.4 devoid of primary antibodies.
Appropriate mixtures of the antibodies and of the corre-
sponding blocking peptides (Ab2 – Cayman Chemical,
360107; Ab3 – Santa Cruz Biotechnology, (N20) P, sc-1746
P), prepared according to the manufacturer’s instruction,
were used to evaluate the specificity of the antibodies in
immunohistochemical assays.
Negative control sections did not produce detectable
DAB precipitates. The expression of COX-2 by keratino-
cytes of normal human skin was considered positive
control.
Microscopic examinations and digital imaging were car-
ried out using the BX41 microscope with white-light illu-
mination (Olympus Optical Co., Tokyo, Japan) equipped
with digital camera and image analysis software (analySIS
3.2, Soft Imaging System, Hanover, Germany).Evaluation of immunostaining
Immunohistochemical scoring was carried out for ten
fields of view at 400× magnification and involved deter-
mining the percentage fraction of positively stained cells
for epithelium and tumour stroma. The cells were
counted separately in central and peripheral regions of
the lesions and also in the areas of normal tissues sur-
rounding the lesions. The final data on the percentage
fractions of COX-2-positive cells were presented as
weighted mean values ± standard deviation. The staining
intensity was also taken into consideration and was
Table 1 Reagents and conditions of the immunohistochemical detection of COX-2 in formalin-fixed paraffin-embedded
breast cancer lesions
Ab1 Ab2 Ab3
Antigen retrieval heating up in 0.01 M citrate buffer pH 6.0 in a
microwave oven (650 W) for 10 minutes
Blocking serum* 1.5% normal goat serum 1.5% normal horse serum 1.5% normal rabbit serum
Type of primary antibody rabbit monoclonal antibody (SP21 clone,
RM-1921, Thermo Fisher Scientific,
Waltham, Massachusetts, USA)
mouse monoclonal antibody (CX229
clone, 160112, Cayman Chemical, Ann
Arbor, Michigan, USA)
goat polyclonal antibody (N-20,
sc-1746, Santa Cruz Biotechnology,
Santa Cruz, California, USA)
Antibody dilution (v/v in
PBS pH 7.4)
1:100 1:200 1:500
Incubation period overnight at 4°C, in a humid chamber
Antibody detection system* Vectastain Elite ABC Kits appropriate for each type of primary antibodies
Peroxidase substrate 0.05% 3,3′ diaminobenzidine (DAB, Sigma-Aldrich, St. Louis,
Missouri, USA) with 0.01% H2O2 and 0.06% NiCl2
(Sigma-Aldrich) in Tris–HCl buffer, pH 7.4
Counterstaining* nuclear red
*(Vector Laboratories, Burlingame, California, USA).
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blue or black staining).
Raw data from the present study were also analyzed
using algorithms used by the authors who received
contradictory results [3,16]. Ristimaki et al. [3] scored
the COX-2-positive cells and calculated percentage frac-
tions of the cells showing moderate and/or high staining
intensity. Richardsen et al. [16] assessed COX-2 expres-
sion by calculating the staining index SI defined as a
weighted sum of percentage fractions of cells showing
various intensity of staining calculated by multiplying
the staining intensity (graded 1–3) by the percentage of
positively stained cells. In the present study the staining
intensity was categorized as weak or high. To ensure the
comparability of our results and those of Richardsen
et al. [16], the weights of 1.0 and 3.0 were assigned to
the fractions of the cells showing low (+) and high (++)
intensity of staining respectively.
The tumours were categorized into high versus low
COX-2 expressing groups according to cut-off thresholds
defined as a) a mean percentage fraction of cells expressing
COX-2, regardless of the staining intensity (Algorithm 1 –
ALG1), b) 10% of cells showing moderate or high staining
intensity (Algorithm 2 – ALG2) as used by Ristimaki et al.
[3] and c) as a median value of the SI score changing be-
tween 0–300 (Algorithm 3 – ALG3) as in the study of
Richardsen et al. [16]. The three algorithms are presented
in Table 2 together with resulting data concerning percent-
age fractions of the COX-2 expressing tumours.
Statistical analysis
The probability of overall survival was determined using
the Kaplan-Meier method, and the log–rank test was
used to evaluate differences in survivorship. Coxproportional hazards modeling was used to determine
the value of the COX-2 expression as an independent
prognostic marker. Parameters other than the COX-2
expression levels entered into Cox analyses included
data on expression of HER-2 (0–3), ER (0–3), PR (0–3),
lymph node status (0–1) and tumour size (1–3). All the
analyses were performed with overall survival as the end
point. Statistical analyses were carried out using Medcalc
software package (MedCalc Software, Ostend, Belgium).
Results
COX-2 expression detected with three antibodies and
evaluated using three different immunohistochemical
scoring algorithms
All the three antibodies detected the COX-2 protein in
all the lesions investigated both in the cancer cells and
in the stroma (Figure 1). The detection sensitivity of the
antibodies was assessed by comparing percentage frac-
tions of the COX-2 positive cells detected in tissue sec-
tions of the same lesions. The highest detection
sensitivity was observed for the polyclonal antibody Ab3
targeting the N–end fragment of the COX-2 protein.
The monoclonal antibody Ab2 was ca. 50% less sensitive
compared to the Ab3 antibody. Finally, the Ab1 mono-
clonal antibody detected COX-2 expression in very small
numbers of cells usually demonstrating a low staining
intensity.
For each antibody (Ab1-3) COX-2 expression levels
were estimated using three different algorithms (ALG1-
3). ALG1 and ALG3 classified the tumours as COX-2
positive or negative using experimentally determined
cut-off thresholds (mean or median value of the score)
while ALG2 based on arbitrarily determined cut-off
value of 10%. Each of the three antibodies similarly
Table 2 Epithelial and stromal expression of COX-2 in breast cancers investigated
ALG 1: percentage fraction of the COX-2
positive cells (0–100) with a mean value
of all the results used for recognition of
tumour overexpressing the COX-2
protein
ALG 2: percentage fraction of the
COX-2 positive cells (0–100) with a
cut-off of 10% used for recognition
of tumour overexpressing the COX-2
protein
ALG 3: percentage fraction of the COX-2
positive cells (0–100) × staining intensity
(1–3) with a median value of all the results
used for recognition of tumour overexpressing
the COX-2 protein
Anti-COX-2 antibody Ab1 Ab2 Ab3 Ab1 Ab2 Ab3 Ab1 Ab2 Ab3
Type of the cells scored (E – epithelial; S – stromal) E S E S E S E S E S E S E S E S E S
Cut-off value 5.1 4.2 21.1 9.8 43.0 19.0 10% of the cells with a moderate or
strong staining
6.2 8.2 27.3 15.3 68.0 30.1
Percentage fraction of the tumours overexpressing COX-2 41.5 41.5 51.2 39.0 46.3 48.8 0 2.4 26.8 29.3 26.8 80.5 48.8 48.8 48.8 48.8 48.8 46.3


















Figure 1 COX-2 staining in invasive ductal breast carcinoma
(T2N1). Immunoreactivity of the polyclonal (Ab3: a) and monoclonal
(Ab2: b; Ab1: c) antibodies, original magnifications: 100× and in
insets 400 × .
Table 3 Statistical significance of the correlations




ALG 1 NS 0.007 0.032
ALG 2 - 0.043 0.020
ALG 3 NS 0.007 NS
Cox model including
expression of ER, PR
and HER
ALG 1 NS NS 0.017
ALG 2 - NS NS





ALG 1 NS 0.036 NS
ALG 2 - NS 0.050
ALG 3 NS 0.001 NS
Cox model including all
the parameters (ER, PR,
HER-2, pT and pN)
ALG 1 NS NS NS
ALG 2 - NS NS
ALG 3 NS 0.002 NS
(NS - not significant).
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tumours if either ALG1 or ALG3 were used for the
evaluation of the expression of the protein within indi-
vidual lesions (ALG1: 41.5%-48.8%; ALG3: 46.3%-48.8%
of the COX-2 positive lesions). However, the same raw
staining data interpreted using the ALG2 scoring system
yielded dramatically scattered results ranging from 0% to80% of the lesions expressing COX-2 depending on the
antibody used in the experiments (see Table 2 for a brief
presentation of the algorithms and the results of the
classification of the tumours).
Prognostic value of COX-2 expression in tumour epithelial
cells
Kaplan-Meier analyses were carried out for the same
group of tumours immunohistochemically examined for
COX-2 expression using three different primary anti-
bodies and three different algorithms selecting the tu-
mours overexpressing the protein in the epithelial cells.
The results illustrating statistical significance of a rela-
tionship between COX-2 expression and overall survival
are presented in Table 3 (three upper rows).
It can be easily seen that the outcome of Kaplan-Meier
analyses was strongly dependent on the type of the anti-
body used for the COX-2 detection. No correlation be-
tween COX-2 expression and patient survival was found
using the data obtained with the Ab1 antibody, inde-
pendently of the algorithm used for separating the tu-
mours expressing and non-expressing the protein in the
epithelial cells. On the other hand both the antibodies
Ab2 and Ab3 yielded data demonstrating statistically
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survival with P2 = 0.007 and P3 = 0.032 respectively for
the tumours selected for high COX-2 expression using
ALG1 and with P2 = 0.043 and P3 = 0.02 for the same set
of data analyzed with ALG2. Interestingly, using ALG3
we found statistically significant association of COX-2
expression with patient prognosis only for the data ob-
tained with the monoclonal Ab2 antibody (P2 = 0.007)
(Figure 2).
In all the statistically significant cases the enhanced
COX-2 expression in tumour epithelial cells had nega-
tive influence on the outcome with relatively high hazard
ratios (HR) for overall survival (ALG 1: HR(Ab2) = 10.01Figure 2 Kaplan-Meier analysis of overall survival and COX-2 staining
Ab1 (a), Ab2 (b) and Ab3 (c) antibodies and evaluated using the algorithm
expression; 1 – high expression.[95% CI 2.69 – 37.29], HR(Ab3) = 4.75 [95% CI 1.26 –
17.79]; ALG 2: HR(Ab2) = 3.56 [95% CI 0.8 – 15.78], HR
(Ab3) = 2.71 [95% CI 0.57 – 12.52]; ALG 3: HR(Ab2) =
10.01 [95% CI 2.69 – 37.29].
However, as shown by multivariate analysis the COX-2
expression in the cancer epithelial cells was not an inde-
pendent risk factor if other variables like expression of
hormone receptors ER and PR, HER-2 as well as tumour
size (pT) and a presence of nodal metastases (pN) were
taken into account. At such an approach analyses based
on Cox proportional hazard model yielded widely varied
results. The analysis including all the parameters showed
statistically significant association between the enhancedin the cancer epithelial cells. COX-2 expression was detected with
s ALG1 (upper row), ALG2 (middle row) and ALG3 (lower row). 0 – low
Table 4 Statistical significance of the correlations




ALG 1 0.0001 0.0001 0.0070
ALG 2 NS 0.0001 NS
ALG 3 0.0006 0.0005 0.0360
Cox model including
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data obtained with the Ab2 antibody and processed
using the ALG3 algorithm. Similar prognostic value of
the COX-2 expression was also found for the raw data
obtained with the Ab3 antibody processed with the
ALG1 algorithm (Table 3) if only the expression of the
receptors was included in the model. Models concerning
only clinico-pathological parameters (pT and pN) indi-
cated such a correlation for combinations of Ab2 with
ALG1 and ALG3 or Ab3 with ALG2 (Table 3).expression of ER, PR
and HER
ALG 1 0.0002 0.0001 0.0100
ALG 2 NS 0.0005 NS





ALG 1 0.0006 0.0002 0.0200
ALG 2 NS 0.0001 NS





ALG 1 0.0002 0.0001 0.0150
ALG 2 NS 0.0001 NS
ALG 3 0.0029 0.0040 0.0200
(NS - not significant).Prognostic value of COX-2 expression in tumour stromal
cells
The results obtained for the COX-2 expression in the
stromal cells were more consistent compared to those
found for the tumour epithelial component. Both in uni-
variate and multivariate analyses COX-2 expression was
significantly correlated with a worse survival independ-
ently of the algorithm used for processing the raw im-
munohistochemical data (Table 4, Figure 3). The results
obtained for all the three antibodies were very similar if
the raw data were evaluated using the algorithms ALG1
and ALG3. It should be noted, however, that in the case
of the ALG2 algorithm the cut-off threshold defining the
COX-2-positive tumours was set at a level of 10% of
tumour cells demonstrating medium or strong staining
intensity. According to that algorithm only one COX-2-
positive lesion was detected in experiments with the
Ab1 antibody while for the same group of the lesions
the experiment using the Ab2 antibody showed as many
as 33 (80%) COX-2-positive cases.Discussion
Variability of immunohistochemical staining with dif-
ferent antibodies detecting the same molecular target
has been reported by several groups. Already in 2003
Garewall et al. [28] described differences in the staining
patterns of three commercially available anti-COX-2
antibodies in human colonic tissues. Kuźbicki et al. [26]
found significant differences in sensitivity of the three
antibodies detecting the same protein in human melan-
oma. Similar effects were described for other widely
used commercial antibodies, most recently for the anti-
bodies used for detecting tumour-suppressor protein
p16INK4a [27].
This work demonstrated considerable differences in
sensitivity of immunohistochemical detection of the
COX-2 protein expression in human breast cancer tis-
sues with the three antibodies used earlier by several au-
thors. The detection sensitivity estimated by percentage
fractions of the stained cells detected in the same lesions
with individual antibodies was much higher for the anti-
bodies Ab2 and Ab3 than for the antibody Ab1.However, the problem of the differences between the
data on the COX-2 expression in breast cancer reported
by different groups cannot be reduced to variability in
the staining sensitivity of antibodies used. Even the
groups working with the same type of primary anti-
bodies obtained inconsistent results concerning the
changes of COX-2 expression during the disease pro-
gression and the prognostic significance of the protein
[3,4,8,12-15,17-19]. Therefore, in our study the raw im-
munohistochemical data obtained with each of the three
antibodies were processed using three algorithms of
assessing the levels of COX-2 expression. Two of those
systems were previously used by other groups (see for
instance [3,16]).
Evaluation of a prognostic impact of the COX-2 ex-
pression revealed significant differences between the re-
sults obtained for the epithelial cancer cells and for the
tumour stroma. COX-2 expression by the epithelial cells
assayed with the Ab1 antibody did not provide prognostic
information independently of the algorithm used for
processing the immunohistochemical data. Prognostic
value of the assays carried out using the Ab2 and Ab3
antibodies varied widely between the algorithms of
Figure 3 Kaplan-Meier analysis of overall survival and COX-2 staining in the cancer stromal cells. COX-2 expression was detected with the
Ab1 (a), Ab2 (b) and Ab3 (c) antibodies and evaluated using the algorithms ALG1 (upper row), ALG2 (middle row) and ALG3 (lower row). 0 – low
expression; 1 – high expression.
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entering COX-2 expression with expression of ER, PR and
HER-2 and clinico-pathological characteristics of the
tumours investigated yielded even more varied results. It
should be noted, however, that the data obtained with
Ab2 antibody and evaluated using the ALG2 algorithm
yielded prognostic value of the COX-2 expression similar
to that reported by Ristimaki et al. [3] who applied similar
approach in the study using tissue micro-arrays.
Examination of cells of the tumour stroma demon-
strated the prognostic value of COX-2 expression inde-
pendently of the antibodies used in the experiments.
The only exception were some of the results obtainedfor the raw immunohistochemical data processed with
the ALG2 algorithm. A plausible cause of this discrep-
ancy seems to be the low cut-off threshold assumed in
the ALG2 for differentiating between the COX-2 positive
and negative tumours. Contrary to the ALG2 the algo-
rithms ALG1 and ALG3 do not involve arbitrary defin-
ition of the cut-off thresholds but instead “adjust” the
cut-off levels to the sensitivity of the immunohistochem-
ical reaction defining the threshold value as either a
median or a mean value of the immunohistochemical
score. Thus, despite significant differences in the sensi-
tivities of the antibodies used, the ALG1 and ALG3
yielded for all the antibodies the data consistently
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levels of the COX-2 expression in the stromal cells and a
worse overall patient survival. It is possible that the cut-
off level of 10% of the COX-2 positive cells applied in
the ALG2 algorithm according to Ristimaki et al. [3] was
implicitly tuned by the authors to the sensitivity of the
Ab2 antibody used in their study.
To the best of our knowledge only two groups carried
out studies of the prognostic value of the COX-2 expres-
sion in the stromal cells of human breast cancer [16,19].
Nakopoulou et al. [19] did not find significant correl-
ation between the COX-2 expression in the stromal cells
and the patient survival while Richardsen et al. [16]
found that high stromal staining intensity in the primary
tumours was associated with significantly higher risk of
death compared to the low staining group. Our study
demonstrated that stromal expression of COX-2 evalu-
ated according to the algorithms ALG1 (this work) and
ALG3 (used according to [16]) could be considered an
independent prognostic factor for the breast cancer.
Interactions between cancer cells and their stroma
change dynamically during disease progression and may
play a role in both inhibiting and promoting tumour
growth and invasiveness [24,29]. There is a large body of
data indicating that the stroma may be a major regulator
of tumour growth. Also, a broad range of evidence
points to a significant role of chronic inflammation in
promoting tumour development although the immune
system most probably also plays a role in resisting for-
mation of neoplasias [29,30]. The expression of inflam-
matory mediators leads to expression of COX-2 which
in turn supports chronic inflammation by mediating
tumour promoting signaling pathways [29-33]. Tumour
promoting role of COX-2 has been shown in several
model systems of mammary tumorigenesis [1,34-36].
Moreover overexpression of COX-2 was found in several
human cancers [1,2]. Our immunohistochemical study
with its natural limitations does not allow for determin-
ing molecular background of the discovered correlation
between the enhanced stromal expression of COX-2 and
worse prognosis for the breast cancer patients. It is well-
known, however, that increased levels of COX-2 may be
involved in controlling many cellular processes including
cell proliferation and survival, inhibition of apoptosis,
angiogenesis and invasiveness of the tumour cells.
Conclusions
Our findings emphasize that the stromal, not epithelial
expression of COX-2 might be an independent prognos-
tic parameter for breast cancer. Moreover, our study
demonstrates that the prognostic value of immunohisto-
chemical assessment the stromal COX-2 expression is
relatively independent of differences in sensitivities of
the primary antibodies if the cut-off thresholds used fordefining the cancers overexpressing COX-2 are properly
tuned to the sensitivity of the antibodies used for a de-
tection of the enzyme.
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